Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853183 | 0.79 | CCR1 (0.39) | AGXTHTTRECQLCCR1CCR5 | |
| SCHEMBL23302010 | 0.79 | RORC (0.33) | HTTRECQLTSHR | |
| SCHEMBL7845798 | 0.76 | AGXT (0.52) | AGXTHTTRECQLCCR1CCR5 | |
| SCHEMBL13674949 | 0.76 | GAA (0.33) | HTTRECQLMAPTCASP1AURKA | |
| SCHEMBL23264653 | 0.75 | UHRF1 (0.38) | AGXTHTTRECQLMAPTCASP1 | |
| SCHEMBL5942430 | 0.75 | CA2 (0.40) | AGXTMAPTCASP1TSHR | |
| SCHEMBL14853023 | 0.74 | MAPT (0.38) | AGXTHTTRECQLCCR1CCR5 | |
| SCHEMBL23723880 | 0.74 | AGXT (0.34) | AGXTHTTRECQLCCR1CCR5 | |
| SCHEMBL21634877 | 0.74 | GAA (0.32) | HTTRECQLMAPTCASP1TSHR | |
| SCHEMBL14853139 | 0.74 | AGXT (0.34) | AGXTHTTRECQLCCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | NOVIRA THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| EP-4051672-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650988-A | Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases | 詹森生物科技公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2021084500-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-2982675-B1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | EISAI R&D MAN CO LTD (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-9573947-B2 | Salt of pyrazoloquinoline derivative, and crystal thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160046623-A1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2982675-A1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2016-02-10 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2646425-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | Boehringer Ingelheim International GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| WO-2013051639-A1 | PYRAZOLOQUINOLINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | AGXT 1989/4885HTT 1703/4885RECQL 240/4885 |
| US-20160046623-A1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | ME1, TST, ME3 | AGXT 626/4885HTT 724/4885RECQL 932/4885 |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | AGXT 800/4885HTT 2688/4885RECQL 4381/4885 |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | DHODH, NQO2, DPYD | AGXT 1964/4885HTT 1444/4885RECQL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.